ArticleThe Journal of biological chemistry2026
Piezo1 accelerates osteoarthritis progression via promotion of HBB-dependent oxidative phosphorylation.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanosensitive ion channel Piezo1 serves as a key regulator of osteoarthritis (OA) progression, but the underlying mechanism remains largely unknown. In the present study, Piezo1 was found to be upregulated in the articular cartilage of mice with post-traumatic (PT), caused by destabilization of the medial meniscus (DMM) or anterior cruciate ligament transection (ACLT) surgery, or obesity-induced OA, but not in age-related OA. This elevated Piezo1 expression triggered a signaling cascade via the KDM6B/KLF1 axis, leading to increased expression of hemoglobin subunit beta (HBB) in chondrocytes. The upregulation of HBB initially enhanced mitochondrial oxidative phosphorylation (OXPHOS), but subsequently impaired mitochondrial function owing to excessive reactive oxygen species (ROS) production, thereby driving chondrocytes an energy metabolism shift from OXPHOS to glycolysis to meet the energy requirements. Notably, intra-articular injection of cartilage-targeting nanoparticles (CAP-PEI) loaded with siRNA against either Piezo1 or HBB effectively restored mitochondrial OXPHOS capacity and attenuated OA progression in mice. Together, these results demonstrate that Piezo1 exacerbates PT and obesity-induced OA by upregulating HBB through the KDM6B/KLF1 pathway, highlighting the therapeutic potential of targeting this metabolic axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.